Mar. 31 at 1:13 PM
BREAKING:
$NVO x Telehealth Expansion = Pressure on
$HIMS?
👉Click to view @NasdaqPulse for timely updates amid the volatility.
Novo Nordisk (
$NVO) just flipped the obesity drug game again. Starting TODAY, Wegovy is rolling out a subscription model — cutting costs by up to
$600/year (oral) and
$1,200/year (injectable).
Distribution isn’t random — it’s strategic:
→ Live now on
$WW,
$LFMD, and Ro
→
$HIMS, Sesame + more platforms coming NEXT
Patients can lock in 3, 6, or 12-month plans, signaling a shift toward recurring revenue + long-term retention.
Read between the lines:
This is BIG pharma going direct-to-consumer via telehealth rails — compressing margins for intermediaries while scaling access FAST.
Watch closely:
•
$NVO → stronger pricing power + volume growth
•
$HIMS → traffic boost OR margin squeeze? depends on rev split
• Telehealth sector → entering pharma partnership phase
This isn’t just pricing — it’s distribution disruption.
